Kenvue Inc.

Kenvue is the J&J consumer-health spinoff that owns Tylenol, Motrin, Band-Aid, Neutrogena, Aveeno, Zyrtec, Listerine, and Nicorette — a fortress-like brand portfolio in over-the-counter medicine, skincare, and essential health products. The stock is up 8.6% year-to-date but down 14% over twelve months, coiling at 54th percentile of the 52-week range going into the August 6 print.

Where the mechanics actually stand:

• Growth is steady but modest: Q1 revenue grew 4.5% year-on-year to $3.91B on 58% gross margin and 22% operating margin — this is the specific consumer-staples profile that pays a 4.5% dividend while compounding modestly at the top line.
• The valuation is not obviously cheap: 22.6x trailing P/E for mid-single-digit revenue growth reflects the brand-quality premium that Kenvue commands versus commodity CPG peers, and the market has been slow to fully reprice that after the J&J spin.
• The Tylenol autism/ADHD litigation is the fresh overhang: a US appeals court just revived private lawsuits linking Tylenol to autism and ADHD — this is a reserved-for accounting exposure that could grow if plaintiffs succeed, though Kenvue's response is that the science does not support the claims.
• The chart is holding: shares 4% above the 50-day and 8% above the 200-day, at 54th percentile of the 52-week range — a grinder with modest constructive momentum.

The August 6 earnings is the coil-release event — a beat with FY26 organic revenue guide holding plus concrete pricing-power commentary and any update on the Tylenol litigation reserves is what breaks the range higher toward $22, while another slower-growth quarter combined with expanding litigation costs is what would extend the coiling into a re-test of the 200-day.